SIMLANDI
Google image searchProduct monograph
Active ingredient
adalimumab, 40 MG/0.4 ML
DIN: 02523957
Dosage form(s): SOLUTION
Route(s) of administration: SUBCUTANEOUS
Description: AUTO-INJECTOR
Schedule: Prescription / Schedule D
Company: JAMP PHARMA CORPORATION
Date: 13-APR-2022
ATC:
- L04 — IMMUNOSUPPRESSANTS (ATC, ATC/DDD, )
- L04A — IMMUNOSUPPRESSANTS (ATC, ATC/DDD)
- L04AB — Tumor necrosis factor alpha (TNF-alpha) inhibitors (ATC, ATC/DDD)
- L04AB04 — ADALIMUMAB (ATC/DDD)
Reference brand drug: Humira
Pharmaceutical standard: MFR
